Oruka Therapeutics reported interim results from a phase 2a study of its experimental monoclonal antibody ORKA-001 in patients with moderate-to-severe plaque psoriasis, showing that 63.5% of treated participants achieved complete skin clearance after 16 weeks. The findings met the primary endpoint of the mid-stage trial and were associated with a rise in the company’s share price, which opened about 30% higher at $89.50 and increased 27.1% in early trading.
The randomized trial enrolled 84 participants, who received two injections of ORKA-001 or placebo one month apart. By week 16, 40 of 63 patients treated with the therapy achieved complete clearance on the Psoriasis Area and Severity Index (PASI), compared to 1 of 21 patients in the placebo group. The drug also outperformed placebo across other measures of psoriasis symptoms, indicating broader improvements beyond the primary endpoint.
ORKA-001 targets interleukin-23 (IL-23), specifically the p19 subunit, an immune protein involved in inflammation associated with psoriasis. The treatment is administered as an under-the-skin injection and is designed to remain in the body longer, allowing dosing as infrequently as once or twice a year. Updated phase 1 data, together with the phase 2a findings, continue to support the potential for annual dosing in patients. Currently approved treatments for this condition are typically given every 8 to 12 weeks, requiring more frequent administration over time.
Cross-trial comparisons suggest ORKA-001 may show higher rates of complete skin clearance than AbbVie’s Skyrizi, which achieved up to 51% clearance in studies cited in its FDA label. Both treatments target IL-23, though ORKA-001 has been engineered with an extended half-life to support longer duration in the body. Earlier data also showed the drug remained in the bloodstream longer and reached higher blood levels than Skyrizi at the same dose, further supporting its extended activity profile.
Oruka’s chief executive officer, Lawrence Klein, Ph.D., described the findings during a call with analysts, stating: “This is unprecedented efficacy for an IL-23 inhibitor, and combined with the potential for annual dosing, another feature never achieved before in this indication, we think this could be a category-winning profile.” In additional remarks, Klein said the company may include an active comparator in phase 3 trials and noted that it would take a “prudent path” in study design, reflecting a measured approach to further development.
Analysts from Jefferies said the results represented an outright win over Skyrizi based on available comparisons, while Barclays analysts described the therapy as demonstrating a best-in-class profile and noted comparability to UCB’s Bimzelx in terms of response. Jefferies estimated the therapy could generate between $5 billion and $10 billion in sales, while TD Cowen analyst Tyler Van Buren said that, if replicated in later-stage trials, it could exceed $10 billion.
The psoriasis treatment market, which the company estimates is worth over $30 billion, includes therapies such as Bristol Myers Squibb’s Sotyktu, Johnson & Johnson’s Tremfya, and oral treatments including Icotyde, reflecting a competitive landscape. Oruka said it plans to advance ORKA-001 into phase 3 development and expects to share additional data later this year.
Overview of Oruka Trial Results
Oruka Therapeutics has announced encouraging Phase 2a clinical data for its psoriasis treatment candidate ORKA-001. The results show that Oruka achieved 63.5% skin clearance in treated patients, marking a significant milestone for Oruka in dermatology research.
Key Findings from Oruka Study
The study demonstrated that patients receiving Oruka’s ORKA-001 experienced meaningful improvements in disease severity. The 63.5% skin clearance rate highlights the potential effectiveness of the Oruka therapy in reducing psoriasis symptoms compared to baseline conditions.
How Oruka Therapy Works
The investigational drug from Oruka is designed to target inflammatory pathways associated with psoriasis. By modulating immune responses, Oruka aims to reduce plaque formation and improve overall skin health in affected patients.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
